-
Kenya's economy faces climate change risks: World Bank
-
Stocks, dollar rise before key US inflation data
-
After wins abroad, Syria leader must gain trust at home
-
Markets rise ahead of US data, expected Fed rate cut
-
German factory orders rise more than expected
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Georgia's street dogs stir affection, fear, national debate
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Pentagon endorses Australia submarine pact
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
OpenAI strikes deal on US$4.6 bn AI centre in Australia
-
Rains hamper Sri Lanka cleanup after deadly floods
-
Unchecked mining waste taints DR Congo communities
-
Asian markets mixed ahead of US data, expected Fed rate cut
-
French almond makers revive traditions to counter US dominance
-
Aid cuts causing 'tragic' rise in child deaths, Bill Gates tells AFP
-
Abortion in Afghanistan: 'My mother crushed my stomach with a stone'
-
Mixed day for US equities as Japan's Nikkei rallies
-
To counter climate denial, UN scientists must be 'clear' about human role: IPCC chief
-
Facebook 'supreme court' admits 'frustrations' in 5 years of work
-
South Africa says wants equal treatment, after US G20 exclusion
-
One in three French Muslims say suffer discrimination: report
-
Microsoft faces complaint in EU over Israeli surveillance data
-
Milan-Cortina organisers rush to ready venues as Olympic flame arrives in Italy
-
Truth commission urges Finland to rectify Sami injustices
-
Stocks rise eyeing series of US rate cuts
-
Italy sweatshop probe snares more luxury brands
-
EU hits Meta with antitrust probe over WhatsApp AI features
-
Russia's Putin heads to India for defence, trade talks
-
South Africa telecoms giant Vodacom to take control of Kenya's Safaricom
-
Markets mixed as traders struggle to hold Fed cut rally
-
Asian markets mixed as traders struggle to hold Fed cut rally
-
In Turkey, ancient carved faces shed new light on Neolithic society
-
Asian markets stumble as traders struggle to hold Fed cut rally
-
Nintendo launches long-awaited 'Metroid Prime 4' sci-fi blaster
-
Trump scraps Biden's fuel-economy standards, sparking climate outcry
-
US stocks rise as weak jobs data boosts rate cut odds
-
Poor hiring data points to US economic weakness
-
Germany to host 2029 women's Euros
-
Satellite surge threatens space telescopes, astronomers warn
-
Greek govt warns farmers not to escalate subsidy protest
-
EU agrees deal to ban Russian gas by end of 2027
-
Former king's memoirs hits bookstores in Spain
-
German lithium project moves ahead in boost for Europe's EV sector
-
Stock markets mostly rise awaiting US data
-
Norway postpones deep-sea mining activities for four years
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN